NR2F1 and breast cancer: Notably, NR2F1 transcript levels were found to be lower in human epidermal growth factor receptor 2 (HER2)-negative breast cancers (that mostly are ER-positive), as compared with the more aggressive HER2-positive breast cancers (Figure 7B).